This study evaluated the clinical outcomes of a combined method of scraping corneal epithelium, coagulating vessels, and subconjunctival bevacizumab in Descemet stripping automated endothelial keratoplasty (DSAEK) for bullous keratopathy with corneal neovascularization (NV).
Methods
The study included patients with bullous keratopathy undergoing DSAEK. Indications for DSAEK were advanced pseudophakic bullous keratopathy with superficial and deep corneal vascularization and failed corneal grafts. Patients were treated by scraping the corneal epithelium and lightly coagulating the corneal superficial stromal NV and the feeding vessels in the sclera, with a subconjunctival bevacizumab injection at the end of surgery. Subconjunctival and perilimbal bevacizumab dose of 2.5 mg/0.1 mL/affected quadrant was injected at the site of NV in each patient at the end of surgery. One or 2 injections were applied. At each visit, a full eye examination with photographic documentation was performed. Mean follow-up period was 32 (24–36) months.
Results
Eight eyes of 8 patients with high-risk corneal transplantation and corneal NV were included in this noncomparative interventional case series. The original corneal NV disappeared in all patients immediately after surgery. No patient in the series had recurrent corneal NV or rejection during at least 24 months of follow-up.
Conclusions
The combination of scraping, coagulating, and bevacizumab injection in DSAEK is an effective method to treat corneal NV in corneal transplantation for bullous keratopathy.
GohtoY., ObanaA., KanedaK., MikiT.Photodynamic effect of a new photosensitizer ATX-S10 on corneal neovascularization. Exp Eye Res1998; 67: 313–22.
4.
GertenG.Bevacizumab (Avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea2008; 27: 1195–9.
5.
D'AmatoR.J., LoughnanM.S., FlynnE., FolkmanJ.Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA1994; 91: 4082–5.
6.
JoussenA.M., BeeckenW-D, MoromizatoY., SchwartzA., KirchhofB., PoulakiV.Inhibition of inflammatory corneal angiogenesis by TNP-470. Invest Ophthalmol Vis Sci2001; 42: 2510–6.
7.
WuP-C, LiuC-C, ChenC-HInhibition of experimental angiogenesis of cornea by somatostatin. Graefes Arch Clin Exp Ophthalmol2003; 241: 63–9.
8.
HurwitzH., FehrenbacherL., NovotnyW.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med2004; 350: 2335–42.
9.
ScottI.U., BresslerN.M., BresslerS.B.; Diabetic Retinopathy Clinical Research Network Study Group. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Retina2008; 28: 36–40.
BaharI., KaisermanI., McAllumP., RootmanD., SlomovicA.Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res2008; 33: 23–8.
17.
CarrascoM.A.Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea2008; 27: 743–5.
18.
HurmericV., MumcuogluT., ErdurmanC., KurtB., DagliO., DurukanA.H.Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea2008; 27: 357–62.
19.
BockF., OnderkaJ., DietrichT.Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci2007; 48: 2545–52.
20.
HosseiniH., KhaliliM.R.Therapeutic potential of bevacizumab (Avastin) in herpetic stromal keratitis (HSK). Med Hypotheses2007; 69: 568–70.
21.
ManzanoR.P., PeymanG.A., KhanP.Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol2007; 91: 804–7.
22.
DastjerdiM.H., Al-ArfajK.M., NallasamyN.Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol2009; 127: 381–9.
23.
KimS.W., HaB.J., KimE.K., TchahH., KimT.I.The effect of topical bevacizumab on corneal neovascularization. Ophthalmology2008; 115: e33–8.
PapathanassiouM., TheodossiadisP.G., LiarakosV.S., RouvasA., Giamarellos-BourboulisE.J., VergadosI.A.Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol2008; 145: 424–31.
28.
QianC.X., BaharI., LevingerE., RootmanD.Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea2008; 27: 1090–2.
FerraraN., GerberH.P., LeCouterJ.The biology of VEGF and its receptors. Nat Med2003; 9: 669–76.
31.
HashemianM.N., MoghimiS., KiumehrS., RiaziM., AmoliF.A.Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Ophthalmic Res2009; 42: 90–5.
32.
FerraraN., DamicoL., ShamsN., LowmanH., KimR.Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina2006; 26: 859–70.
33.
FerraraN., MassR.D., CampaC., KimR.Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med2007; 58: 491–504. Review.
HosseiniH., NowroozzadehM.H., SaloutiR., NejabatM.Anti-VEGF therapy with bevacizumab for anterior segment eye disease. Cornea2012; 31: 322–34. Review.
36.
CapellaM.J., Alvarez de ToledoJ., de la PazM.F.[Limbal stem cell deficiency following multiple intravitreal injections.]Arch Soc Esp Oftalmol2011; 86: 89–92.
37.
YouI.C., ImS.K., LeeS.H., YoonK.C.Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization. Cornea2011; 30: 30–3.
38.
Chun-ChiChiang, Jane-MingLin, Yi-YuTsai. Combined scraping, coagulation, and subconjunctival bevacizumab in corneal transplantation for bullous keratopathy with corneal neovascularization. Taiwan J Ophthalmol2011; 1: 21–4.
